Drug Trial Radar · NCT06512428
A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Jul 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
138
Planned (sponsor's estimate)
Start
Mar 15, 2024
Primary completion
Jan 30, 2026
Study completion Jan 30, 2026
Sponsor
- Lead sponsor
- Shanghai Runshi Pharmaceutical Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of simmitinib plus irinotecan liposome in the treatment of advanced esophageal squamous cell carcinoma, and to evaluate the PK of the drug and the correlation between biomarkers and clinical efficacy of simmitinib plus irinotecan liposome.
Conditions
- Advanced Esophageal Squamous Cell Carcinoma
Interventions
simmitinib plus irinotecan liposomeDrug
simmitinib plus irinotecan liposome 70 mg/m\^2 every 2 weeks
irinotecan liposomeDrug
irinotecan liposome 70 mg/m\^2 every 2 weeks
irinotecanDrug
irinotecan 180mg/m\^2 every 2 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation Phase: DLTTime frame: From Cycle 1 Day 1 to Cycle 1 Day 28 (each cycle is 28 days)
- Dose Escalation Phase: AETime frame: From first dose to 30 days post the last dose
- Randomized controlled study phase: ORRTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Harbin Medical University Cancer Hospital
Heilongjiang, Harbin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.